Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin

Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Rami S. Komrokji, Kathy McGraw, Jaroslaw Maciejewski, Jessica K. Altman, Puneet S. Cheema, David F. Claxton, Selina M. Luger, Ryan J. Mattison, Timothy R. Wassenaar, Andrew S. Artz, Charles A. Schiffer, Mark R. Litzow, Martin S. Tallman

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology